Voluntary Pause of Enrollment in Ph 2 LOTIS-9 Trial of ZYNLONTA (loncastuximab tesirine-lpyl) and Rituximab in Unfit/Frail 1L DLBCL Patients Announced July 19, 2023
Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL reported July 19, 2023
Supplemental NDA submitted to FDA for BRUKINSA + obinutuzumab in R/R follicular lymphoma July 19, 2023
European Commission approves fixed-duration Columvi (glofitamab) for people with R/R DLBCL July 19, 2023
Positive Topline Results from Ph 1/2 EPCORE™ NHL-1 Trial of Epcoritamab in Patients with R/R Follicular Lymphoma announced July 5, 2023
NEOGAP acquires TCER Oncology AB, strengthening its position in personalised immunotherapy June 28, 2023
Ph 3 Trial of ADCETRIS (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with 3-Year PFS of 94.9% vs Less Tolerable SoC in cHL June 28, 2023
ICML 2023: Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in R/R FL and MCL in TRANSCEND Clinical Trials June 28, 2023
Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications initiated June 21, 2023
Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy June 21, 2023
6-Year OS Results Added to US Prescribing Information for ADCETRIS® (brentuximab vedotin) as 1L Treatment for Advanced Hodgkin Lymphoma June 21, 2023
First Patient Dosed in Ph 1/2 Study of ONCT-808 in patients with R/R aggressive B-cell lymphoma June 13, 2023
TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi in R/R FL and MCL Meet Primary Endpoint of ORR May 10, 2023
CHMP recommends EU approval of Roche’s fixed-duration Columvi (glofitamab) for people with R/R DLBCL May 10, 2023
